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Abstract
How and when a tumor acquires metastatic properties remain
largely unknown. Recent work has uncovered an intricate new
mechanism through which transforming growth factor-beta (TGFβ)
acts in concert with oncogenic Ras to antagonize p63-metastasis
protective function. p63 inhibition requires the combined action of
Ras-activated mutant p53 and TGFβ-induced Smads. Mecha-
nistically, it involves the formation of a p63-Smads-mutant p53
ternary complex. Remarkably, just two of the key downstream
targets of p63 turn out to be sufficient as a prognostic tool for
breast cancer metastasis. Moreover, the molecular mechanism of
this inhibition points to novel therapeutic possibilities.
The molecular mechanisms and oncogenic lesions that
cooperate to generate metastatic tumors remain poorly
understood. While a number of metastasis-promoting factors
have been identified, those that suppress it are few and far
between. Wild-type p53 is best known for its tumor
suppressor function. However, elegant mouse models [1-3]
and human molecular epidemiology [4] data have revealed
that mutant p53, in concert with oncogenic Ras mutations
[5], is also a dominant prometastatic factor. These effects of
Ras have a parallel in the context of transforming growth
factor-beta (TGFβ)/Smads signaling, which is best known for
its growth inhibitor activities. However, in end-stage tumors
and/or during epithelial cancer progression, TGFβ promotes
metastasis [6]. Although the underlying molecular mecha-
nisms have not been elucidated, there is evidence to suggest
that oncogenic Ras empowers TGFβ metastatic potential [7].
Exploring these events in breast cancer cell lines and
xenograph mouse models, Adorno and colleagues [8] provide
evidence that the prometastatic switches of mutant p53 and
TGFβ involve a common complex mechanism: in response to
oncogenic Ras, mutant p53 and TGFβ cooperate to oppose
the activity of p63, itself a transcription factor and a key
regulator of stem cell fate in epithelial tissues. The effect is
facilitated by Smads, downstream effectors of TGFβ which
act as a scaffold allowing mutant p53 to inactivate p63 trans-
criptional activity, most likely by interfering with its recruitment
to the promoter regions of its target genes. Crucially, the
formation of the p63-containing ternary complex is dependent
on the level of both TGFβ and oncogenic Ras signaling.
The study thus identifies p63 as one of the very few
suppressors of metastasis known to date and uncovers an
intricate mechanism that antagonizes metastasis in cancer
cells in response to TGFβ. But why cancer cells would
employ such an elaborate mechanism to inactivate p63
remains unclear. p63-inactivating mutations or bi-allelic loss
could indeed be selected for during tumor progression as a
more efficient, and irreversible, means to lose p63 function.
One possibility is that p63 function is required for the
establishment of a secondary tumor once the cancer cells
have migrated from the primary tumor to distant metastatic
sites. Consistent with this possibility is the role of p63 as an
important regulator of the proliferative potential of epithelial
stem cells [9].
The data presented in the article by Adorno and colleagues
[8] also suggest that TGFβ in cooperation with oncogenic
Ras is a potent inducer of epithelial mesenchymal transition
(EMT), a form of phenotypic and functional plasticity that is an
integral process during development and that is recapitulated
during malignant progression of epithelial tumors [10]. p63
opposes TGFβ-induced EMT, and according to the proposed
model, the p53 status appears to be an important
determinant for EMT response upon TGFβ exposure. This
exciting possibility demands to be tested further.
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Adorno and colleagues [8] show that Smads directly bind to
p63 in cancer cells and that this complex allows the recruit-
ment of mutant p53. A p63/Smad complex may therefore
also exist in healthy epithelial cells. The existence and the
relevance of such a complex should be further explored,
especially in the context of embryonic development. Of note
is a previous discovery by the same group that binding
between the Smads and wild-type p53 is required for TGFβ
signaling during mesoderm formation in Xenopus [11].
The authors also identify two key p63 targets that mediate its
antimetastatic activity: Sharp1, a regulator of circadian
oscillations, and Cyclin G2, a protein that promotes cell cycle
arrest in response to DNA damage. However, the mecha-
nisms by which these genes suppress metastasis remain to
be elucidated. How a protein involved in circadian oscillations
could function as an inhibitor of metastasis is not immediately
clear.
Using a panel of 1,200 primary breast tumors and associated
clinical data, the authors went on to clinically validate Sharp1
and Cyclin G2 as important prognostic tools for breast
cancer metastasis. Provocatively, they propose that these
two genes provide a minimal metastatic signature with which
breast cancer patients can be stratified according to the
metastatic propensity of their tumors. This is especially
striking since neither gene has previously been identified in
known gene expression signatures that predict breast cancer
metastasis and poor disease-free survival [12]. Further
support for this claim is eagerly awaited as these findings are
putatively of tremendous value given that the current
molecular profiling involves screening of multiple gene signa-
tures (MammaPrint relies on 70 genes and recurrence score
on 21 genes). It will also be interesting to further explore the
prognostic value of these two genes in other tumor types,
especially those of epithelial origin.
In addition to providing the molecular mechanistic insights
and diagnostic leads, the study points to new therapy
possibilities. Targeting the mutant p53-Smads-p63 ternary
complex with small molecules that inhibit the Smads-p63
interaction and/or mutant p53 binding to the Smads-p63
complex may represent an option for therapeutic intervention.
Since the authors also show that Ras-mediated CK1δ/ε-
dependent phosphorylation of mutant p53 is required for the
formation of this complex, inhibitors of this kinase could
efficiently interfere with the metastatic process. Promisingly,
such inhibitors are already in various clinical trials.
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